Fatty Acid Synthase and Its Inhibitors in Endometrial Cancer

doi:10.12280/gjszjk.20230328

Abstract

Abstract:

Fatty acid synthase (FASN) is a key enzyme in the fatty acid synthesis that catalyzes the de novo synthesis of lipids. Most of the fatty acids are of food origin in normal tissues, while fatty acids are dependent on the de novo synthesis of lipids in endometrial cancer cells. Previous studies have shown that FASN expression is associated with the development, progression and poor prognosis of endometrial malignancies. The overexpression of FASN is correlated with mitogen extracellular kinase (MEK)/ extracellular signal-regulated kinase (ERK)/ mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) signaling pathways. Specific blockade of its activity can significantly inhibit the growth and proliferation of tumor cells. We review the action of FASN and mechanism in endometrial malignancies and the progress of FASN inhibitors such as C75, C93, orlistat and so on, in endometrial cancer or other tumors, with the aim of providing new ideas for the treatment of endometrial tumors.

Key words: Fatty acid synthases, Enzyme inhibitors, Therapy, Prognosis, Endometrial neoplasms

FENG Ya-ru, LI Xue, ZHANG Hui-ying. Fatty Acid Synthase and Its Inhibitors in Endometrial Cancer[J]. Journal of International Reproductive Health/Family Planning, 2024, 43(1): 79-82.

References 29

[1]	Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(9):860-877. doi: 10.1016/j.annonc.2022.05.009. pmid: 35690222
[2]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3):212-220. doi: 10.3760/cma.j.cn112152-20220922-00647.
[3]	Ding S, Madu CO, Lu Y. The Impact of Hormonal Imbalances Associated with Obesity on the Incidence of Endometrial Cancer in Postmenopausal Women[J]. J Cancer, 2020, 11(18):5456-5465. doi: 10.7150/jca.47580. pmid: 32742493
[4]	Bian X, Liu R, Meng Y, et al. Lipid metabolism and cancer[J]. J Exp Med, 2021, 218(1):e20201606. doi: 10.1084/jem.20201606.
[5]	Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies[J]. Oncogenesis, 2023, 12(1):16. doi: 10.1038/s41389-023-00460-8. pmid: 36934087
[6]	Fhu CW, Ali A. Fatty Acid Synthase: An Emerging Target in Cancer[J]. Molecules, 2020, 25(17):3935. doi: 10.3390/molecules25173935.
[7]	Wu ZS, Huang SM, Wang YC. Palmitate Enhances the Efficacy of Cisplatin and Doxorubicin against Human Endometrial Carcinoma Cells[J]. Int J Mol Sci, 2021, 23(1):80. doi: 10.3390/ijms23010080.
[8]	Zhang J, Song Y, Shi Q, et al. Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis[J]. Front Med, 2021, 15(5):649-656. doi: 10.1007/s11684-021-0830-0.
[9]	Chi C, Harth L, Galera MR, et al. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL[J]. Cancers(Basel), 2022, 14(18):4491. doi: 10.3390/cancers14184491.
[10]	Mozihim AK, Chung I, Said N, et al. Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?[J]. Metabolites, 2022, 12(4):350. doi: 10.3390/metabo12040350.
[11]	Tsuji T, Yoshinaga M, Togami S, et al. Fatty acid synthase expression and clinicopathological findings in endometrial cancer[J]. Acta Obstet Gynecol Scand, 2004, 83(6):586-590. doi: 10.1111/j.0001-6349.2004.00511.x.
[12]	Anagnostou E, Miliaras D, Meditskou S, et al. Immunohistochemical investigation of metabolic markers fatty acid synthase (FASN) and glucose transporter 1 (GLUT1) in normal endometrium, endometrial hyperplasia, and endometrial malignancy[J]. Hippokratia, 2017, 21(4):169-174. pmid: 30944506
[13]	Butler LM, Perone Y, Dehairs J, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention[J]. Adv Drug Deliv Rev, 2020, 159:245-293. doi: 10.1016/j.addr.2020.07.013.
[14]	Sebastiani V, Visca P, Botti C, et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma[J]. Gynecol Oncol, 2004, 92(1):101-105. doi: 10.1016/j.ygyno.2003.10.027. pmid: 14751145
[15]	Rahman MT, Nakayama K, Ishikawa M, et al. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer[J]. Oncology, 2013, 84(3):166-173. doi: 10.1159/000342967. pmid: 23306391
[16]	Raab S, Lefebvre T. Fatty acid synthase, a "multi-FASet" enzyme[J]. Med Sci(Paris), 2022, 38(5):445-452. doi: 10.1051/medsci/2022062.
[17]	Qu H, Shan K, Tang C, et al. A novel small-molecule fatty acid synthase inhibitor with antitumor activity by cell cycle arrest and cell division inhibition[J]. Eur J Med Chem, 2021, 219:113407. doi: 10.1016/j.ejmech.2021.113407.
[18]	Singh S, Karthikeyan C, Moorthy N. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents[J]. Mini Rev Med Chem, 2020, 20(18):1820-1837. doi: 10.2174/1389557520666200811100845.
[19]	Menendez JA, Peirce SK, Papadimitropoulou A, et al. Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer[J]. Aging(Albany NY), 2020, 12(24):24671-24692. doi: 10.18632/aging.202289.
[20]	Pandey PR, Liu W, Xing F, et al. Anti-cancer drugs targeting fatty acid synthase (FAS)[J]. Recent Pat Anticancer Drug Discov, 2012, 7(2):185-197. doi: 10.2174/157489212799972891. pmid: 22338595
[21]	Chaturvedi S, Biswas M, Sadhukhan S, et al. Role of EGFR and FASN in breast cancer progression[J]. J Cell Commun Signal, 2023, 17(4):1249-1282. doi: 10.1007/s12079-023-00771-w.
[22]	Wysham WZ, Roque DR, Han J, et al. Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines[J]. Target Oncol, 2016, 11(6):763-769. doi: 10.1007/s11523-016-0442-9. pmid: 27188391
[23]	Xu G, Zhao Z, Wysham WZ, et al. Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer[J]. Front Oncol, 2023, 13:1219923. doi: 10.3389/fonc.2023.1219923.
[24]	Çetinkaya M, Baran Y. Therapeutic Potential of Luteolin on Cancer[J]. Vaccines(Basel), 2023, 11(3):554. doi: 10.3390/vaccines11030554.
[25]	Prasher P, Sharma M, Singh SK, et al. Luteolin: a flavonoid with a multifaceted anticancer potential[J]. Cancer Cell Int, 2022, 22(1):386. doi: 10.1186/s12935-022-02808-3. pmid: 36482329
[26]	Kciuk M, Alam M, Ali N, et al. Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications[J]. Molecules, 2023, 28(13):5246.doi: 10.3390/molecules28135246.
[27]	Oh JE, Jung BH, Park J, et al. Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics[J]. Cells, 2020, 9(11):2447. doi: 10.3390/cells9112447.
[28]	Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges[J]. Nat Rev Drug Discov, 2022, 21(4):283-305. doi: 10.1038/s41573-021-00367-2. pmid: 35031766
[29]	Bruce SF, Wu S, Ribeiro JR, et al. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis[J]. Gynecol Oncol, 2023, 172:98-105. doi: 10.1016/j.ygyno.2023.03.008. pmid: 37003074